Title :

Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care.

Author(s) :

Daste, Camille [Auteur]
Rannou, François [Auteur]
Mouthon, Luc [Auteur]
Sanchez, Katherine [Auteur]
Roren, Alexandra [Auteur]
Tiffreau, Vincent [Auteur]
Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - EA 7369
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995
Thoumie, Philippe [Auteur]
Cabane, Jean [Auteur]
Chatelus, Emmanuel [Auteur]
Sibilia, Jean [Auteur]
Poiraudeau, Serge [Auteur]
Nguyen, Christelle [Auteur]

Journal title :

Seminars in arthritis and rheumatism

Abbreviated title :

Semin. Arthritis Rheum.

Publication date :

2018-03-27

ISSN :

1532-866X

English keyword(s) :

Minimal clinically important difference
Patient acceptable symptom state
Systemic sclerosis
Patient-reported outcomes

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

To estimate patient acceptable symptom state (PASS) and minimal clinically important difference (MCID) for patient-reported outcomes in systemic sclerosis (SSc). We conducted a secondary analysis of the SCLEREDUC trial, a ...
Show more >To estimate patient acceptable symptom state (PASS) and minimal clinically important difference (MCID) for patient-reported outcomes in systemic sclerosis (SSc). We conducted a secondary analysis of the SCLEREDUC trial, a 12-month randomized controlled trial comparing the efficacy of physical therapy to usual care in 220 SSc patients followed-up from September 2005 to October 2010. Self-rated state and change in patient health at 12 months were assessed by using 2 external anchors extracted from the Medical Outcomes Study 36-Item Short-Form. Patients who self-rated their health as "excellent", "very good" or "good" were the PASS group and those who self-rated their health change as "somewhat better" were the MCID group. Main outcomes were the estimates of PASS by using the 75th percentile method and of MCID by using the mean change in scores method for pain and activity limitation. PASS (95% confidence interval) and mean (SD) MCID estimates at 12 months were 53.75 (34.00 to 68.00) and -6.74 (32.02) for the joint-pain visual analog scale (range 0-100), 1.41 (1.13 to 1.63) and -0.21 (0.48) for the Health Assessment Questionnaire (HAQ, range 0-3), 1.27 (1.07 to 1.62) and -0.13 (0.45) for the scleroderma HAQ (range 0-3), 26.00 (17.00 to 37.00) and -3.38 (9.87) for the Cochin Hand Function Scale (range 0-90), and 19.40 (17.20 to 21.90) and -5.69 (6.79) for the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (range 0-30), respectively. We provide, for the first time, the PASS and MCID estimates for pain and activity limitation in SSc. ClinicalTrials.gov Identifier: NCT00318188. First Posted: April 26, 2006.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Univ. Littoral Côte d’Opale
Univ. Artois
Université de Lille
Inserm

Collections :

• Lille Inflammation Research International Center (LIRIC) - U995
• Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS) - EA 7369

Research team(s) :

Activité Physique, Muscle, Santé (APMS)

Submission date :

2019-09-24T10:01:40Z